Effect of growth hormone, glutamine, and diet on adaptation in short- bowel syndrome: A randomized, controlled study

J. Scolapio, Michael Camilleri, C. R. Fleming, L. V. Oenning, D. D. Burton, T. J. Sebo, K. P. Batts, D. G. Kelly

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

Background and Aims: The effects of parenteral growth hormone, glutamine supplementation, and a high carbohydrate-low fat (HCLF) diet on gut adaptation in short-bowel syndrome are unclear. The afro of this study was to compare effects of this treatment regimen and placebo in patients with short- bowel syndrome. Methods: A randomized, 6-week, double-blind, placebo- controlled, crossover study in 8 patients with short-bowel syndrome (average small bowel length, 71 cm; mean duration, 12.9 years) was performed. Active treatment was growth hormone (0.14 mg·kg-1·day-1), oral glutamine (0.63 g·kg-1·day-1), and the HCLF diet for 21 days. The weight, basal metabolic rate, nutrient and electrolyte balance, serum insulin-like growth factor I levels, D-xylose absorption, morphology and DNA proliferation of small intestinal mucosa, and gastrointestinal transit were evaluated. Treatments were compared by paired t test. Results: Active treatment transiently increased body weight, significantly but modestly increased the absorption of sodium and potassium, and decreased gastric emptying. The assimilation of macronutrients, stool volumes, and morphometry of small bowel mucosa were not statistically different in the two treatment arms. Conclusions: Although treatment with growth hormone, glutamine, and HCLF diet for 3 weeks resulted in modest improvements in electrolyte absorption and delayed gastric emptying, there were no improvements in small bowel morphology, stool losses, or macronutrient absorption.

Original languageEnglish (US)
Pages (from-to)1074-1081
Number of pages8
JournalGastroenterology
Volume113
Issue number4
DOIs
StatePublished - 1997

Fingerprint

Short Bowel Syndrome
Glutamine
Growth Hormone
Diet
Fat-Restricted Diet
Gastric Emptying
Carbohydrates
Therapeutics
Placebos
Gastrointestinal Transit
Basal Metabolism
Water-Electrolyte Balance
Xylose
Intestinal Mucosa
Insulin-Like Growth Factor I
Cross-Over Studies
Electrolytes
Potassium
Mucous Membrane
Sodium

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Effect of growth hormone, glutamine, and diet on adaptation in short- bowel syndrome : A randomized, controlled study. / Scolapio, J.; Camilleri, Michael; Fleming, C. R.; Oenning, L. V.; Burton, D. D.; Sebo, T. J.; Batts, K. P.; Kelly, D. G.

In: Gastroenterology, Vol. 113, No. 4, 1997, p. 1074-1081.

Research output: Contribution to journalArticle

Scolapio, J. ; Camilleri, Michael ; Fleming, C. R. ; Oenning, L. V. ; Burton, D. D. ; Sebo, T. J. ; Batts, K. P. ; Kelly, D. G. / Effect of growth hormone, glutamine, and diet on adaptation in short- bowel syndrome : A randomized, controlled study. In: Gastroenterology. 1997 ; Vol. 113, No. 4. pp. 1074-1081.
@article{b70783a6404e4d229803249d42841771,
title = "Effect of growth hormone, glutamine, and diet on adaptation in short- bowel syndrome: A randomized, controlled study",
abstract = "Background and Aims: The effects of parenteral growth hormone, glutamine supplementation, and a high carbohydrate-low fat (HCLF) diet on gut adaptation in short-bowel syndrome are unclear. The afro of this study was to compare effects of this treatment regimen and placebo in patients with short- bowel syndrome. Methods: A randomized, 6-week, double-blind, placebo- controlled, crossover study in 8 patients with short-bowel syndrome (average small bowel length, 71 cm; mean duration, 12.9 years) was performed. Active treatment was growth hormone (0.14 mg·kg-1·day-1), oral glutamine (0.63 g·kg-1·day-1), and the HCLF diet for 21 days. The weight, basal metabolic rate, nutrient and electrolyte balance, serum insulin-like growth factor I levels, D-xylose absorption, morphology and DNA proliferation of small intestinal mucosa, and gastrointestinal transit were evaluated. Treatments were compared by paired t test. Results: Active treatment transiently increased body weight, significantly but modestly increased the absorption of sodium and potassium, and decreased gastric emptying. The assimilation of macronutrients, stool volumes, and morphometry of small bowel mucosa were not statistically different in the two treatment arms. Conclusions: Although treatment with growth hormone, glutamine, and HCLF diet for 3 weeks resulted in modest improvements in electrolyte absorption and delayed gastric emptying, there were no improvements in small bowel morphology, stool losses, or macronutrient absorption.",
author = "J. Scolapio and Michael Camilleri and Fleming, {C. R.} and Oenning, {L. V.} and Burton, {D. D.} and Sebo, {T. J.} and Batts, {K. P.} and Kelly, {D. G.}",
year = "1997",
doi = "10.1053/gast.1997.v113.pm9322500",
language = "English (US)",
volume = "113",
pages = "1074--1081",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Effect of growth hormone, glutamine, and diet on adaptation in short- bowel syndrome

T2 - A randomized, controlled study

AU - Scolapio, J.

AU - Camilleri, Michael

AU - Fleming, C. R.

AU - Oenning, L. V.

AU - Burton, D. D.

AU - Sebo, T. J.

AU - Batts, K. P.

AU - Kelly, D. G.

PY - 1997

Y1 - 1997

N2 - Background and Aims: The effects of parenteral growth hormone, glutamine supplementation, and a high carbohydrate-low fat (HCLF) diet on gut adaptation in short-bowel syndrome are unclear. The afro of this study was to compare effects of this treatment regimen and placebo in patients with short- bowel syndrome. Methods: A randomized, 6-week, double-blind, placebo- controlled, crossover study in 8 patients with short-bowel syndrome (average small bowel length, 71 cm; mean duration, 12.9 years) was performed. Active treatment was growth hormone (0.14 mg·kg-1·day-1), oral glutamine (0.63 g·kg-1·day-1), and the HCLF diet for 21 days. The weight, basal metabolic rate, nutrient and electrolyte balance, serum insulin-like growth factor I levels, D-xylose absorption, morphology and DNA proliferation of small intestinal mucosa, and gastrointestinal transit were evaluated. Treatments were compared by paired t test. Results: Active treatment transiently increased body weight, significantly but modestly increased the absorption of sodium and potassium, and decreased gastric emptying. The assimilation of macronutrients, stool volumes, and morphometry of small bowel mucosa were not statistically different in the two treatment arms. Conclusions: Although treatment with growth hormone, glutamine, and HCLF diet for 3 weeks resulted in modest improvements in electrolyte absorption and delayed gastric emptying, there were no improvements in small bowel morphology, stool losses, or macronutrient absorption.

AB - Background and Aims: The effects of parenteral growth hormone, glutamine supplementation, and a high carbohydrate-low fat (HCLF) diet on gut adaptation in short-bowel syndrome are unclear. The afro of this study was to compare effects of this treatment regimen and placebo in patients with short- bowel syndrome. Methods: A randomized, 6-week, double-blind, placebo- controlled, crossover study in 8 patients with short-bowel syndrome (average small bowel length, 71 cm; mean duration, 12.9 years) was performed. Active treatment was growth hormone (0.14 mg·kg-1·day-1), oral glutamine (0.63 g·kg-1·day-1), and the HCLF diet for 21 days. The weight, basal metabolic rate, nutrient and electrolyte balance, serum insulin-like growth factor I levels, D-xylose absorption, morphology and DNA proliferation of small intestinal mucosa, and gastrointestinal transit were evaluated. Treatments were compared by paired t test. Results: Active treatment transiently increased body weight, significantly but modestly increased the absorption of sodium and potassium, and decreased gastric emptying. The assimilation of macronutrients, stool volumes, and morphometry of small bowel mucosa were not statistically different in the two treatment arms. Conclusions: Although treatment with growth hormone, glutamine, and HCLF diet for 3 weeks resulted in modest improvements in electrolyte absorption and delayed gastric emptying, there were no improvements in small bowel morphology, stool losses, or macronutrient absorption.

UR - http://www.scopus.com/inward/record.url?scp=0030856777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030856777&partnerID=8YFLogxK

U2 - 10.1053/gast.1997.v113.pm9322500

DO - 10.1053/gast.1997.v113.pm9322500

M3 - Article

C2 - 9322500

AN - SCOPUS:0030856777

VL - 113

SP - 1074

EP - 1081

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -